TGF-β, bone morphogenetic protein, and activin signaling and the tumor microenvironment

Cold Spring Harbor Perspectives in Biology

Volumn 9, Issue 5, 2017, Pages

  Pickup, Michael W ^a,b   Owens, Philip ^a,c   Moses, Harold L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; BONE MORPHOGENETIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; HUMAN; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ACTIVINS; ANIMALS; BONE MORPHOGENETIC PROTEINS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 85018759435     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a022285     Document Type: Review

References (184)

1. Achyut BR, Bader DA, Robles AI, Wangsa D, Harris CC, Ried T, Yang L. 2013. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet 9: e1003251.
2. Akhurst RJ, Hata A. 2012. Targeting the TGF-β signalling pathway in disease. Nat Rev Drug Discov 11: 790–811.
3. Akman HO, Zhang H, Siddiqui MA, Solomon W, Smith EL, Batuman OA. 2001. Response to hypoxia involves transforming growth factor-β2 and Smad proteins in human endothelial cells. Blood 98: 3324–3331.
4. Aleman-Muench GR, Soldevila G. 2012. When versatility matters: Activins/inhibins as key regulators of immunity. Immunol Cell Biol 90: 137–148.
5. Allan DS, Rybalov B, Awong G, Zuniga-Pflucker JC, Kopcow HD, Carlyle JR, Strominger JL. 2010. TGF-β affects development and differentiation of human natural killer cell subsets. Eur J Immunol 40: 2289–2295.
6. Allinson KR, Lee HS, Fruttiger M, McCarty JH, Arthur HM. 2012. Endothelial expression of TGF-β type II receptor is required to maintain vascular integrity during postnatal development of the central nervous system. PLoS ONE 7: e39336.
7. Amendt C, Schirmacher P, Weber H, Blessing M. 1998. Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 17: 25–34.
8. Antsiferova M, Werner S. 2012. The bright and the dark sides of activin in wound healing and cancer. J Cell Sci 125: 3929–3937.
9. Baker AM, Bird D, Lang G, Cox TR, Erler JT. 2013. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene 32: 1863–1868.
10. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, et al. 2010. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 16: 1009–1017.
11. Beavis PA, Stagg J, Darcy PK, Smyth MJ. 2012. CD73: A potent suppressor of antitumor immune responses. Trends Immunol 33: 231–237.
12. Bein K, Simons M. 2000. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275: 32167–32173.
13. Bergamaschi A, Tagliabue E, Sorlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, et al. 2008. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 214: 357–367.
14. Bergers G, Benjamin LE. 2003. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401–410.
15. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. 2004. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848–851.
16. Bieniasz M, Oszajca K, Eusebio M, Kordiak J, Bartkowiak J, Szemraj J. 2009. The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer 66: 319–326.
17. Bierie B, Moses HL. 2006. TGFβ: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506–520.
18. Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL. 2008. Transforming growth factor-β regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 68: 1809–1819.
19. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL. 2009. Abrogation of TGFβ signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 119: 1571–1582.
20. Biswas SK, Mantovani A. 2010. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 11: 889–896.
21. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Bottinger EP. 2000. A mechanism of suppression of TGF-β/SMAD signaling by NF-kB/RelA. Genes Dev 14: 187–197.
22. Boak AM, Roy R, Berk J, Taylor L, Polgar P, Goldstein RH, Kagan HM. 1994. Regulation of lysyl oxidase expression in lung fibroblasts by transforming growth factor-β1 and prostaglandin E2. Am J Respir CellMol Biol 11: 751–755.
23. Bommireddy R, Pathak LJ, Martin J, Ormsby I, Engle SJ, Boivin GP, Babcock GF, Eriksson AU, Singh RR, Doetschman T. 2006. Self-antigen recognition by TGF b1-deficient T cells causes their activation and systemic inflammation. Lab Invest 86: 1008–1019.
24. Border WA, Noble NA. 1994. Transforming growth factor β in tissue fibrosis. N Engl J Med 331: 1286–1292.
25. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, et al. 2007. Mammographic density and the risk and detection of breast cancer. N Engl J Med 356: 227–236.
26. Busch S, Acar A, Magnusson Y, Gregersson P, Ryden L, Landberg G. 2015. TGF-β receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in premenopausal breast cancer. Oncogene 34: 27–38.
27. Byrne SN, Knox MC, Halliday GM. 2008. TGF-β is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction. Immunol Cell Biol 86: 92–97.
28. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, Sevillano M, Nadal C, Jung P, Zhang XH, et al. 2012. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 22: 571–584.
29. Cejalvo T, Sacedon R, Hernandez-Lopez C, Diez B, Gutierrez- Frias C, Valencia J, Zapata AG, Varas A, Vicente A. 2007. Bone morphogenetic protein-2/4 signalling pathway components are expressed in the human thymus and inhibit early T-cell development. Immunology 121: 94–104.
30. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, Derangere V, Vincent J, Masson D, et al. 2012. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 36: 362–373.
31. Chambers RC, Leoni P, Kaminski N, Laurent GJ, Heller RA. 2003. Global expression profiling of fibroblast responses to transforming growth factor-β1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol 162: 533–546.
32. Chang H, Huylebroeck D, Verschueren K, Guo Q, Matzuk MM, Zwijsen A. 1999. Smad5 knockout mice die at midgestation due to multiple embryonic and extraembryonic defects. Development 126: 1631–1642.
33. Cheifetz S, Hernandez H, Laiho M, ten Dijke P, Iwata KK, Massague J. 1990. Distinct transforming growth factor β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J Biol Chem 265: 20533–20538.
34. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 198: 1875–1886.
35. + T cells in glioma patients. Neuro Oncol 12: 7–13.
36. Criswell TL, Dumont N, Barnett JV, Arteaga CL. 2008. Knockdown of the transforming growth factor-β type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res 68: 7304–7312.
37. Dang D, Yang Y, Li X, Atakilit A, Regezi J, Eisele D, Ellis D, Ramos DM. 2004. Matrix metalloproteinases and TGFβ1 modulate oral tumor cell matrix. Biochem Biophys Res Commun 316: 937–942.
38. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. 2007. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953–1961.
39. Davis BN, Hilyard AC, Lagna G, Hata A. 2008. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454: 56–61.
40. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. 1993. Transforming growth factor-β1 induces a-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122: 103–111.
41. Diebold RJ, Eis MJ, Yin M, Ormsby I, Boivin GP, Darrow BJ, Saffitz JE, Doetschman T. 1995. Early-onset multifocal inflammation in the transforming growth factor β1- null mouse is lymphocyte mediated. Proc Natl Acad Sci 92: 12215–12219.
42. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. 2007. The type III TGF-β receptor suppresses breast cancer progression. J Clin Invest 117: 206–217.
43. Duitman J, Borensztajn KS, Pulskens WP, Leemans JC, Florquin S, Spek CA. 2014.CCAAT-enhancer binding protein delta (C/EBPd) attenuates tubular injury and tubulointerstitial fibrogenesis during chronic obstructive nephropathy. Lab Invest 94: 89–97.
44. Dumont N, Liu B, Defilippis RA, Chang H, Rabban JT, Karnezis AN, Tjoe JA, Marx J, Parvin B, Tlsty TD. 2013. Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia 15: 249–262.
45. Ellis LM. 2006. The role of neuropilins in cancer. Mol Cancer Ther 5: 1099–1107.
46. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ. 2006. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222–1226.
47. Falanga V, Qian SW, Danielpour D, Katz MH, Roberts AB, Sporn MB. 1991. Hypoxia upregulates the synthesis of TGF-β1 by human dermal fibroblasts. J Invest Dermatol 97: 634–637.
48. Ferrara N, Hillan KJ, Gerber HP, Novotny W. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391–400.
49. Fessing MY, Atoyan R, Shander B, Mardaryev AN, Botchkarev VV Jr, Poterlowicz K, Peng Y, Efimova T, Botchkarev VA. 2010. BMP signaling induces cell-type-specific changes in gene expression programs of human keratinocytes and fibroblasts. J Invest Dermatol 130: 398–404.
50. + T-cells when naive but promotes their survival and function once antigen experienced: Atwo-faced impact on autoimmunity. Diabetes 57: 2684–2692.
51. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, et al. 2008. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518–527.
52. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. 2010. The polarization of immune cells in the tumour environment by TGFβ. Nat Rev Immunol 10: 554–567.
53. Fordyce CA, Patten KT, Fessenden TB, DeFilippis R, Hwang ES, Zhao J, Tlsty TD. 2012.Cell-extrinsic consequences of epithelial stress: Activation of protumorigenic tissue phenotypes. Breast Cancer Res 14: R155.
54. Franses JW, Baker AB, Chitalia VC, Edelman ER. 2011. Stromal endothelial cells directly influence cancer progression. Sci Transl Med 3: 66ra65.
55. Freudlsperger C, Bian Y, ContagWise S, Burnett J, Coupar J, Yang X, Chen Z, Van Waes C. 2013. TGF-β and NF-kB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers. Oncogene 32: 1549–1559.
56. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. 2009. Polarization of tumorassociated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell 16: 183–194.
57. Fumagalli M, Musso T, Vermi W, Scutera S, Daniele R, Alotto D, Cambieri I, Ostorero A, Gentili F, Caposio P, et al. 2007. Imbalance between activin A and follistatin drives postburn hypertrophic scar formation in human skin. Exp Dermatol 16: 600–610.
58. Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Wang J. 2013. TGF-β suppresses VEGFA-mediated angiogenesis in colon cancer metastasis. PLoS ONE 8: e59918.
59. Germain RN. 2002. T-cell development and the CD4–CD8 lineage decision. Nat Rev Immunol 2: 309–322.
60. Gorelik L, Flavell RA. 2000. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12: 171–181.
61. Guillot N, Kollins D, Gilbert V, Xavier S, Chen J, Gentle M, Reddy A, Bottinger E, Jiang R, Rastaldi MP, et al. 2012. BAMBI regulates angiogenesis and endothelial homeostasis through modulation of alternative TGFβ signaling. PLoS ONE 7: e39406.
62. Gunturi A, Berg RE, Crossley E, Murray S, Forman J. 2005. The role of TCR stimulation and TGF-β in controlling the expression of CD94/NKG2A receptors on CD8 T cells. Eur J Immunol 35: 766–775.
63. Hanahan D, Coussens LM. 2012. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309–322.
64. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57–70.
65. Hardwick JC, Kodach LL, Offerhaus GJ, van den Brink GR. 2008. Bone morphogenetic protein signalling in colorectal cancer. Nat Rev Cancer 8: 806–812.
66. Harrison CA, Wiater E, Gray PC, Greenwald J, Choe S, Vale W. 2004. Modulation of activin and BMP signaling. Mol Cell Endocrinol 225: 19–24.
67. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, ten Dijke P. 2010. Matrix metalloproteinase- 14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 70: 4141–4150.
68. Hazelbag S, Gorter A, Kenter GG, van den Broek L, Fleuren G. 2002. Transforming growth factor-β1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum Pathol 33: 1193–1199.
69. 3H]thymidine uptake by rat thymocytes and 3T3 cells in vitro. Mol Cell Endocrinol 61: 133–138.
70. Hida K, Hida Y, Shindoh M. 2008. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 99: 459–466.
71. Hidalgo L, Martinez VG, Valencia J, Hernandez-Lopez C, Vazquez MN, Nunez JR, Zapata AG, Sacedon R, Varas A, Vicente A. 2012. Expression of BMPRIA on human thymic NK cell precursors: Role of BMP signaling in intrathymic NK cell development. Blood 119: 1861–1871.
72. + induced regulatory T cells. J Immunol 182: 4633–4640.
73. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62: 65–74.
74. Izumi N, Mizuguchi S, Inagaki Y, Saika S, Kawada N, Nakajima Y, Inoue K, Suehiro S, Friedman SL, Ikeda K. 2006. BMP-7 opposes TGF-β1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol 290: L120–L126.
75. Jinka R, Kapoor R, Sistla PG, Raj TA, Pande G. 2012. Alterations in cell-extracellular matrix interactions during progression of cancers. Int J Cell Biol 2012: 219196.
76. Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nat Rev Cancer 6: 392–401.
77. Karin N. 2010. The multiple faces of CXCL12 (SDF-1a) in the regulation of immunity during health and disease. J Leukoc Biol 88: 463–473.
78. Karlsson G, Blank U, Moody JL, Ehinger M, Singbrant S, Deng CX, Karlsson S. 2007. Smad4 is critical for selfrenewal of hematopoietic stem cells. J Exp Med 204: 467–474.
79. Kim BG, Li C, Qiao W, Mamura M, Kasprzak B, Anver M, Wolfraim L, Hong S, Mushinski E, Potter M, et al. 2006. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441: 1015–1019.
80. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL, Akporiaye ET. 2003. Transforming growth factor β inhibits the antigen- presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63: 1860–1864.
81. Kojc N, Zidar N, Vodopivec B, Gale N. 2005. Expression of CD34, a-smooth muscle actin, and transforming growth factor β1 in squamous intraepithelial lesions and squamous cell carcinoma of the larynx and hypopharynx. Hum Pathol 36: 16–21.
82. Koli K, Wempe F, Sterner-Kock A, Kantola A, Komor M, Hofmann WK, von Melchner H, Keski-Oja J. 2004. Disruption of LTBP-4 function reduces TGF-β activation and enhances BMP-4 signaling in the lung. J Cell Biol 167: 123–133.
83. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. 1993. Transforming growth factor b1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci 90: 770–774.
84. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA. 2004. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci 101: 4966–4971.
85. Lan Y, Liu B, Yao H, Li F, Weng T, Yang G, Li W, Cheng X, Mao N, Yang X. 2007. Essential role of endothelial Smad4 in vascular remodeling and integrity. Mol Cell Biol 27: 7683–7692.
86. Langenfeld EM, Langenfeld J. 2004. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2: 141–149.
87. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. 2005. TGF-β receptor function in the endothelium. Cardiovasc Res 65: 599–608.
88. Leight JL, Wozniak MA, Chen S, Lynch ML, Chen CS. 2012. Matrix rigidity regulates a switch between TGF-β1-induced apoptosis and epithelial–mesenchymal transition. Mol Biol Cell 23: 781–791.
89. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et al. 2009. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139: 891–906.
90. Li MO, Flavell RA. 2008. TGF-β: A master of all T cell trades. Cell 134: 392–404.
91. Li MO, Wan YY, Flavell RA. 2007. T cell-produced transforming growth factor-β1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 26: 579–591.
92. Lijnen P, Petrov V. 2002. Transforming growth factor-β1- induced collagen production in cultures of cardiac fibroblasts is the result of the appearance of myofibroblasts. Methods Find Exp Clin Pharmacol 24: 333–344.
93. Liu D, Wang J, Kinzel B, Mueller M, Mao X, Valdez R, Liu Y, Li E. 2007. Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity. Blood 110: 1502–1510.
94. Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, Wang X, Wang J, Yu H, Cao X, et al. 2012. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid- derived suppressor cells via targeting of PTEN. J Immunol 188: 5500–5510.
95. Lu P, Weaver VM, Werb Z. 2012. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol 196: 395–406.
96. Lucas PJ, Kim SJ, Melby SJ, Gress RE. 2000. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor β II receptor. J Exp Med 191: 1187–1196.
97. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. 2009. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11: R7.
98. Maegdefrau U, Amann T, Winklmeier A, Braig S, Schubert T, Weiss TS, Schardt K, Warnecke C, Hellerbrand C, Bosserhoff AK. 2009. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol 218: 520–529.
99. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. 2006. Transforming growth factor-β induces development of the TH17 lineage. Nature 441: 231–234.
100. Martinez VG, Hernandez-Lopez C, Valencia J, Hidalgo L, Entrena A, Zapata AG, Vicente A, Sacedon R, Varas A. 2011. The canonical BMP signaling pathway is involved in human monocyte-derived dendritic cell maturation. Immunol Cell Biol 89: 610–618.
101. Martinez VG, Hidalgo L, Valencia J, Hernandez-Lopez C, Entrena A, del Amo BG, Zapata AG, Vicente A, Sacedon R, Varas A. 2014. Autocrine activation of canonical BMP signaling regulates PD-L1 and PD-L2 expression in human dendritic cells. Eur J Immunol 44: 1031–1038.
102. Martinez-Ferrer M, Afshar-Sherif AR, Uwamariya C, de Crombrugghe B, Davidson JM, Bhowmick NA. 2010. Dermal transforming growth factor-β responsiveness mediates wound contraction and epithelial closure. Am J Pathol 176: 98–107.
103. Massagué J. 2008. TGFβ in cancer. Cell 134: 215–230.
104. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. 2009. Inhibition of transforming growth factor β receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 50: 1140–1151.
105. McCarthy SA, Bicknell R. 1993. Inhibition of vascular endothelial cell growth by activin-A. J Biol Chem 268: 23066–23071.
106. Mills CD. 2012. M1 and M2 macrophages: Oracles of health and disease. Crit Rev Immunol 32: 463–488.
107. Min S, Li L, Zhang M, Zhang Y, Liang X, Xie Y, He Q, Li Y, Sun J, Liu Q, et al. 2012. TGF-β-associated miR-27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by TAB3, p38 MAPK, MAP2K4 and MAP2K7. Genes Immun 13: 621–631.
108. Monteiro M, Almeida CF, Caridade M, Ribot JC, Duarte J, Agua-Doce A, Wollenberg I, Silva-Santos B, Graca L. 2010. Identification of regulatory Foxp3+ invariant NKT cells induced by TGF-β. J Immunol 185: 2157–2163.
109. Mukhopadhyay A, Chan SY, Lim IJ, Phillips DJ, Phan TT. 2007. The role of the activin system in keloid pathogenesis. Am J Physiol Cell Physiol 292: C1331–C1338.
110. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL. 2006. Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25: 3408–3423.
111. Murray PJ, Wynn TA. 2011. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11: 723–737.
112. Murray GI, Duncan ME, O’Neil P, Melvin WT, Fothergill JE. 1996.Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461–462.
113. Nakagawa T, Li JH, Garcia G, Mu W, Piek E, Bottinger EP, Chen Y, Zhu HJ, Kang DH, Schreiner GF, et al. 2004. TGFβ induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways. Kidney Int 66: 605–613.
114. Novitskiy SV, Pickup MW, Chytil A, Polosukhina D, Owens P, Moses HL. 2012. Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties. J Leukoc Biol 92: 641–651.
115. Ogawa K, Funaba M. 2011. Activin in humoral immune responses. Vitam Horm 85: 235–253.
116. Ogawa K, Funaba M, Chen Y, Tsujimoto M. 2006. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J Immunol 177: 6787–6794.
117. Okochi-Takada E, Hattori N, Tsukamoto T, Miyamoto K, Ando T, Ito S, Yamamura Y, Wakabayashi M, Nobeyama Y, Ushijima T. 2014. ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis. Oncogene 33: 2273–2278.
118. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. 2013. Suppression, subversion and escape: The role of regulatory T cells in cancer progression. Clin Exp Immunol 171: 36–45.
119. Oshima M, Oshima H, Taketo MM. 1996. TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 179: 297–302.
120. Owens P, Pickup MW, Novitskiy SV, Chytil A, Gorska AE, Aakre ME, West J, Moses HL. 2012. Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proc Natl Acad Sci 109: 2814–2819.
121. Owens P, Polikowsky H, Pickup MW, Gorska AE, Jovanovic B, Shaw AK, Novitskiy SV, Hong CC, Moses HL. 2013. Bone Morphogenetic Proteins stimulate mammary fibroblasts to promote mammary carcinoma cell invasion. PLoS ONE 8: e67533.
122. Owens P, Pickup MW, Novitskiy SV, Giltnane JM, Gorska AE, Hopkins CR, Hong CC, Moses HL. 2014. Inhibition of BMP signaling suppresses metastasis in mammary cancer. Oncogene 34: 2437–2449.
123. Paiva CE, Serrano SV, Paiva BS, Scapulatempo-Neto C, Soares FA, Rogatto SR, Marques ME. 2012. Absence of TGF-βRII predicts bone and lung metastasis and is associated with poor prognosis in stage III breast tumors. Cancer Biomark 11: 209–217.
124. Palucka K, Banchereau J. 2012. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12: 265–277.
125. Panopoulou E, Murphy C, Rasmussen H, Bagli E, Rofstad EK, Fotsis T. 2005. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. Cancer Res 65: 1877–1886.
126. Pardali E, ten Dijke P. 2009. Transforming growth factor-β signaling and tumor angiogenesis. Front Biosci (Landmark Ed) 14: 4848–4861.
127. Pardali E, Goumans MJ, ten Dijke P. 2010. Signaling by members of the TGF-β family in vascular morphogenesis and disease. Trends Cell Biol 20: 556–567.
128. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, et al. 2005. Tensional homeostasis and the malignant phenotype. Cancer Cell 8: 241–254.
129. Payne SL, Hendrix MJ, Kirschmann DA. 2007. Paradoxical roles for lysyl oxidases in cancer—A prospect. J Cell Biochem 101: 1338–1354.
130. Pepper MS. 1997. Transforming growth factor-β: Vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8: 21–43.
131. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y, Lebecque S. 2007. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178: 2763–2769.
132. Pickup M, Novitskiy S, Moses HL. 2013a. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 13: 788–799.
133. Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A, Aakre M, Weaver VM, Moses HL. 2013b. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β deficient mouse mammary carcinoma. Cancer Res 73: 5336–5346.
134. Pickup MW, Hover LD, Polikowsky ER, Chytil A, Gorska AE, Novitskiy SV, Moses HL, Owens P. 2015. BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation. Mol Oncol 9: 179–191.
135. Pinto M, Oliveira C, Cirnes L, Carlos Machado J, Ramires M, Nogueira A, Carneiro F, Seruca R. 2003. Promoter methylation of TGFβ receptor I and mutation of TGFβ receptor II are frequent events in MSI sporadic gastric carcinomas. J Pathol 200: 32–38.
136. Place AE, JinHuh S, Polyak K. 2011. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 13: 227.
137. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. 2006. Collagen reorganization at the tumor–stromal interface facilitates local invasion. BMC Med 4: 38.
138. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ. 2008. Collagen density promotes mammary tumor initiation and progression. BMC Med 6: 11.
139. Qualls JE, Murray PJ. 2011. Tumor macrophages protective and pathogenic roles in cancer development. Curr Top Dev Biol 94: 309–328.
140. Raida M, Clement JH, Leek RD, Ameri K, Bicknell R, Niederwieser D, Harris AL. 2005. Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol 131: 741–750.
141. Reed MJ, Vernon RB, Abrass IB, Sage EH. 1994. TGF-β1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts fromyoung and aged donors. J Cell Physiol 158: 169–179.
142. Robson NC, Wei H, McAlpine T, Kirkpatrick N, Cebon J, Maraskovsky E. 2009. Activin-A attenuates several human natural killer cell functions. Blood 113: 3218–3225.
143. Robson NC, Hidalgo L, McAlpine T, Wei H, Martinez VG, Entrena A, Melen GJ, MacDonald AS, Phythian-Adams A, Sacedon R, et al. 2014. Optimal effector functions in human natural killer cells rely upon autocrine bone morphogenetic protein signaling. Cancer Res 74: 5019–5031.
144. Rocher C, Singla R, Singal PK, Parthasarathy S, Singla DK. 2012. Bone morphogenetic protein 7 polarizes THP-1 cells into M2 macrophages. Can J Physiol Pharmacol 90: 947–951.
145. Roepman P, Wessels LF, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P, Tilanus MG, Koole R, Hordijk GJ, van der Vliet PC, et al. 2005. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 37: 182–186.
146. Roman-Perez E, Casbas-Hernandez P, Pirone JR, Rein J, Carey LA, Lubet RA, Mani SA, Amos KD, Troester MA. 2012. Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res 14: R51.
147. Safina A, Vandette E, Bakin AV. 2007. ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene 26: 2407–2422.
148. Salogni L, Musso T, Bosisio D, Mirolo M, Jala VR, Haribabu B, Locati M, Sozzani S. 2009. Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood 113: 5848–5856.
149. Sartor MA, Mahavisno V, Keshamouni VG, Cavalcoli J, Wright Z, Karnovsky A, Kuick R, Jagadish HV, Mirel B, Weymouth T, et al. 2010. ConceptGen: A gene set enrichment and gene set relation mapping tool. Bioinformatics 26: 456–463.
150. Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, Ben-Aharon I, Beck AH, Dias-Santagata D, Koeva M, Stemmer SM, Whitesell L, et al. 2014. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell 158: 564–578.
151. Scutera S, Riboldi E, Daniele R, Elia AR, Fraone T, Castagnoli C, Giovarelli M, Musso T, Sozzani S. 2008. Production and function of activin A in human dendritic cells. Eur Cytokine Netw 19: 60–68.
152. Semitekolou M, Alissafi T, Aggelakopoulou M, Kourepini E, Kariyawasam HH, Kay AB, Robinson DS, Lloyd CM, Panoutsakopoulou V, Xanthou G. 2009. Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease. J Exp Med 206: 1769–1785.
153. Sideras P, Apostolou E, Stavropoulos A, Sountoulidis A, Gavriil A, Apostolidou A, Andreakos E. 2013. Activin, neutrophils, and inflammation: Just coincidence? Semin Immunopathol 35: 481–499.
154. Sierra-Filardi E, Puig-Kroger A, Blanco FJ, Nieto C, Bragado R, Palomero MI, Bernabeu C, Vega MA, Corbi AL. 2011. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 117: 5092–5101.
155. Simantov R, Silverstein RL. 2003. CD36: A critical anti-angiogenic receptor. Front Biosci 8: s874–882.
156. Sozzani S, Musso T. 2011. The yin and yang of Activin A. Blood 117: 5013–5015.
157. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, et al. 2011. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res 17: 5674–5685.
158. Suzuki Y, Montagne K, Nishihara A, Watabe T, Miyazono K. 2008. BMPs promote proliferation and migration of endothelial cells via stimulation of VEGF-A/VEGFR2 and angiopoietin-1/Tie2 signalling. J Biochem 143: 199–206.
159. Takimoto T, Wakabayashi Y, Sekiya T, Inoue N, Morita R, Ichiyama K, Takahashi R, Asakawa M, Muto G, Mori T, et al. 2010. Smad2 and Smad3 are redundantly essential for the TGF-β-mediated regulation of regulatory T plasticity and Th1 development. J Immunol 185: 842–855.
160. Tanaka H, Shinto O, Yashiro M, Yamazoe S, Iwauchi T, Muguruma K, Kubo N, Ohira M, Hirakawa K. 2010. Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances antitumor activity. Oncol Rep 24: 1637–1643.
161. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. 2002. Inhibition of transforming growth factor-β activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 62: 6021–6025.
162. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. 2011. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29: 235–271.
163. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. 2012. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12: 239–252.
164. Walker RA, Dearing SJ, Gallacher B. 1994. Relationship of transforming growth factor β 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br J Cancer 69: 1160–1165.
165. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL. 2008a. Transforming growth factor β engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 28: 5605–5620.
166. Wang SY, Tai GX, Zhang PY, Mu DP, Zhang XJ, Liu ZH. 2008b. Inhibitory effect of activin A on activation of lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells. Cytokine 42: 85–91.
167. Wei P, Zhao YG, Zhuang L, Ruben S, Sang QX. 2001. Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin β. Biochem Biophys Res Commun 280: 744–755.
168. Whiteside TL, Schuler P, Schilling B. 2012. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 12: 1383–1397.
169. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. 1998. Transforming growth factor b1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37: 19–29.
170. Wiley DM, Kim JD, Hao J, Hong CC, Bautch VL, Jin SW. 2011. Distinct signalling pathways regulate sprouting angiogenesis from the dorsal aorta and the axial vein. Nat Cell Biol 13: 686–692.
171. Woodford-Richens KL, Rowan AJ, Gorman P, Halford S, Bicknell DC, Wasan HS, Roylance RR, Bodmer WF, Tomlinson IP. 2001. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc Natl Acad Sci 98: 9719–9723.
172. Xu H, Silver PB, Tarrant TK, Chan CC, Caspi RR. 2003. TGFβ inhibits activation and uveitogenicity of primary but not of fully polarized retinal antigen-specific memoryeffector T cells. Invest Ophthalmol Vis Sci 44: 4805–4812.
173. Yamashita S, Maeshima A, Kojima I, Nojima Y. 2004. Activin A is a potent activator of renal interstitial fibroblasts. JAm Soc Nephrol 15: 91–101.
174. Yang EY, Moses HL. 1990. Transforming growth factor b1- induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111: 731–741.
175. + myeloid cells that promote metastasis. Cancer Cell 13: 23–35.
176. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y, et al. 2012. TGF-β-miR-34a- CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 22: 291–303.
177. Yashiro R, Nagasawa T, Kiji M, Hormdee D, Kobayashi H, Koshy G, Nitta H, Ishikawa I. 2006. Transforming growth factor-β stimulates interleukin-11 production by human periodontal ligament and gingival fibroblasts. J Clin Periodontol 33: 165–171.
178. Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffman R, Payne S, Longenecker G, Mozes E, Karlsson S. 1996. Autoimmune manifestations in the transforming growth factor-β1 knockout mouse. Blood 87: 1439–1445.
179. Yoshioka Y, Ono M, Osaki M, Konishi I, Sakaguchi S. 2012. Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation. Eur J Immunol 42: 749–759.
180. Yu B, Chen X, Li J, Qu Y, Su L, Peng Y, Huang J, Yan J, Yu Y, Gu Q, et al. 2013. Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression. BMC Cell Biol 14: 17.
181. Zhang XJ, Li Y, Tai GX, Xu GY, Zhang PY, Yang Y, Lao FX, Liu ZH. 2005. Effects of activin A on the activities of the mouse peritoneal macrophages. Cell Mol Immunol 2: 63–67.
182. Zhang M, Herion TW, Timke C, Han N, Hauser K, Weber KJ, Peschke P, Wirkner U, Lahn M, Huber PE. 2011. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. Neoplasia 13: 537–549.
183. Zhou J, Schmid T, Schnitzer S, Brune B. 2006. Tumor hypoxia and cancer progression. Cancer Lett 237: 10–21.
184. Zhou J, Tai G, Liu H, Ge J, Feng Y, Chen F, Yu F, Liu Z. 2009. Activin A down-regulates the phagocytosis of lipopolysaccharide- activated mouse peritoneal macrophages in vitro and in vivo. Cell Immunol 255: 69–75.